Viatris Presents Six Studies on Low-Dose Estrogen Contraceptive Patch at ACOG 2026

Key Takeaways

• Viatris presented six clinical studies on its investigational low-dose estrogen weekly contraceptive patch at ACOG 2026
• The once-weekly transdermal patch aims to provide convenient hormonal contraception for women with potentially reduced side effects
• Data presentations at major medical conferences typically precede regulatory submissions and potential market approval

---

PITTSBURGH - Viatris Inc. (Nasdaq: VTRS) announced the presentation of six clinical abstracts on its investigational low-dose estrogen combined hormonal contraceptive (CHC) weekly patch at the 2026 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting in Washington, D.C., held May 1-3, 2026.

Clinical Development Progress

The investigational treatment represents a once-weekly transdermal contraceptive patch designed for women seeking convenient hormonal birth control options. By delivering hormones through the skin, the patch bypasses first-pass liver metabolism, potentially offering improved tolerability compared to oral contraceptives.

Market Context and Innovation

The contraceptive patch market has seen limited innovation in recent years, with existing weekly patches containing higher hormone doses. Viatris’s low-dose formulation could address patient concerns about hormone exposure while maintaining contraceptive efficacy.

Transdermal delivery systems offer several advantages over oral contraceptives, including consistent hormone levels, reduced gastrointestinal side effects, and improved compliance through weekly rather than daily dosing.

Regulatory and Commercial Outlook

Presenting clinical data at ACOG, the premier professional organization for women’s healthcare providers, signals Viatris’s commitment to advancing this contraceptive option. The company’s participation in this high-profile medical meeting suggests the development program is progressing toward potential regulatory submissions.

The global contraceptive market continues to evolve, with patients and healthcare providers seeking options that balance efficacy, safety, and convenience. Low-dose hormonal formulations have gained favor due to reduced side effect profiles while maintaining contraceptive effectiveness.

Company Strategy

For Viatris, a company focused on providing access to medicines globally, the contraceptive patch represents an opportunity to expand its women’s health portfolio. The company has emphasized developing treatments that address unmet medical needs while remaining accessible to diverse patient populations worldwide.

---

Frequently Asked Questions

What makes this contraceptive patch different from existing options?

Viatris’s investigational patch uses a low-dose estrogen formulation, potentially reducing hormone-related side effects while maintaining contraceptive efficacy through convenient once-weekly dosing.

When will the low-dose contraceptive patch be available to patients?

The patch is still investigational and requires regulatory approval. Timeline for availability depends on clinical trial completion and FDA review, which typically takes several years.

How does a weekly patch compare to daily birth control pills?

Weekly patches offer more consistent hormone levels, eliminate daily dosing requirements, and bypass stomach absorption, potentially reducing gastrointestinal side effects common with oral contraceptives.